17,502 Shares in Vaxcyte, Inc. (NASDAQ:PCVX) Bought by Diversified Trust Co

Diversified Trust Co bought a new position in Vaxcyte, Inc. (NASDAQ:PCVX) in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 17,502 shares of the company’s stock, valued at approximately $1,433,000.

Other large investors have also recently added to or reduced their stakes in the company. Natixis Advisors LLC boosted its position in shares of Vaxcyte by 6.5% during the second quarter. Natixis Advisors LLC now owns 14,091 shares of the company’s stock worth $1,064,000 after buying an additional 861 shares during the period. Rhumbline Advisers boosted its position in Vaxcyte by 7.4% during the 2nd quarter. Rhumbline Advisers now owns 159,295 shares of the company’s stock worth $12,028,000 after acquiring an additional 11,001 shares during the last quarter. Victory Capital Management Inc. grew its stake in shares of Vaxcyte by 9.5% during the 2nd quarter. Victory Capital Management Inc. now owns 307,516 shares of the company’s stock worth $23,221,000 after acquiring an additional 26,641 shares in the last quarter. Arizona State Retirement System raised its holdings in shares of Vaxcyte by 4.1% in the second quarter. Arizona State Retirement System now owns 25,796 shares of the company’s stock valued at $1,948,000 after purchasing an additional 1,013 shares during the last quarter. Finally, Quest Partners LLC bought a new stake in shares of Vaxcyte in the second quarter worth $70,000. Institutional investors own 96.78% of the company’s stock.

Vaxcyte Stock Down 7.1 %

PCVX opened at $81.06 on Thursday. The stock has a market cap of $10.10 billion, a price-to-earnings ratio of -17.62 and a beta of 0.98. Vaxcyte, Inc. has a 12-month low of $58.10 and a 12-month high of $121.06. The business has a 50 day moving average of $91.23 and a 200-day moving average of $93.31.

Vaxcyte (NASDAQ:PCVX) last released its quarterly earnings data on Tuesday, November 5th. The company reported ($0.83) EPS for the quarter, topping analysts’ consensus estimates of ($1.10) by $0.27. During the same quarter in the prior year, the firm earned ($0.91) EPS. As a group, analysts expect that Vaxcyte, Inc. will post -4.14 earnings per share for the current year.

Insider Activity at Vaxcyte

In other news, CEO Grant Pickering sold 15,000 shares of the business’s stock in a transaction dated Friday, November 1st. The shares were sold at an average price of $106.82, for a total value of $1,602,300.00. Following the completion of the sale, the chief executive officer now owns 435,219 shares of the company’s stock, valued at approximately $46,490,093.58. The trade was a 3.33 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CFO Andrew Guggenhime sold 42,000 shares of the business’s stock in a transaction dated Friday, October 18th. The shares were sold at an average price of $115.39, for a total transaction of $4,846,380.00. Following the completion of the sale, the chief financial officer now directly owns 90,383 shares of the company’s stock, valued at $10,429,294.37. This represents a 31.73 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 113,732 shares of company stock worth $11,730,787. Insiders own 3.10% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts have issued reports on PCVX shares. The Goldman Sachs Group assumed coverage on shares of Vaxcyte in a research note on Friday, December 20th. They issued a “buy” rating and a $135.00 price target on the stock. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Vaxcyte in a research report on Wednesday, November 6th. Finally, Needham & Company LLC reissued a “buy” rating and set a $140.00 price target on shares of Vaxcyte in a research report on Wednesday, November 6th. Eight analysts have rated the stock with a buy rating, According to data from MarketBeat, the company currently has a consensus rating of “Buy” and a consensus target price of $145.71.

Vaxcyte Profile

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.